



DEPARTMENT OF PHARMACOLOGY, AIIMS BHOPAL
SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

Ph: 0755-2902620 Email: adr@aiimshhopal.edu.in

For VOLUNTARY reporting of Adverse Drug Reactions by healthcare professionals

Patient ID:		INDIAN PHARMACOPOEIA COMMISSION (National Coordination Center- Pharmacovigilance programme of India) Ministry of health & Family Welfare Government of India Sector-23, Rai Nagar, Gaziabad-201002					(AMC/ NCC Use only)				
							AMC Report No:				
						Worldwide Unique ID:					
A. PATIENT INFORMATION						12. Relevant tests / laboratory data with dates					
*1. Patient Initials	2. Age at time of event or date of birth	3. Sex	M	F		13. Other relevant history including pre-existing medical conditions (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/ renal dysfunction etc)					
		4. Weight		Kgs							
B. SUSPECTED ADVERSE REACTION						14. Seriousness of the reaction					
*5. Date of reaction started (dd/mm/yyyy)						<input type="checkbox"/> Death (dd/mm/yyyy) <input type="checkbox"/> Congenital-anomaly <input type="checkbox"/> Life threatening <input type="checkbox"/> Required intervention to prevent permanent impairment / damage <input type="checkbox"/> Hospitalization/prolonged <input type="checkbox"/> Disability <input type="checkbox"/> Other (specify)					
*6. Date of recovery (dd/mm/yyyy)											
*7. Describe reaction or problem						*15. Outcomes					
						<input type="checkbox"/> Fatal <input type="checkbox"/> Recovering <input type="checkbox"/> Unknown <input type="checkbox"/> Continuing <input type="checkbox"/> Recovered <input type="checkbox"/> Other (specify)					
C. SUSPECTED MEDICATION(S)											
S.No	*8. Name (brand and /or generic name)	Manufacterer (if known)	Batch No./ Lot No. (if known)	Exp. Date (if known)	Dose used	Route used	Frequency	Therapy dates (if known, give duration)		Reason for use / prescribed for	
								Date Started	Date Stoppe		
i.											
ii.											
iii.											
iv.											
S.No As per C	9. Reaction abated after drug stopped or dose Reduced					10. Reaction reappeared after reintroduction					
	Yes	No	Unknown	NA	Reduced dose	Yes	No	Unknown	NA	If reintroduced dose	
i.											
ii.											
iii.											
iv.											
*11. Concomitant medical product including self medication and herbal remedies with therapy dates (exclude those used to treat reaction)						D. REPORTER (see confidentiality section on first page)					
						*16. Name and Professional Address :					
						Pin code: _____					
						E-mail Tel. No. (with STD code): _____					
						Occupation _____ Signature _____					
						17. Causality Assessment				*18. Date of this report (dd/mm/yyyy)	
* These details are essential.											

ADVICE ABOUT REPORTING

- Report adverse experiences with medications
- Report serious adverse reactions. A reaction is serious when the patient outcome is:
 - death
 - life-threatening (real risk of dying)
 - hospitalization (initial or prolonged)
 - disability (significant, persistent or permanent)
 - congenital anomaly
 - required intervention to prevent permanent impairment or damage
- Report even if:
 - You're not certain the product caused adverse reaction
 - You don't have all the details, however, point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.
- Who can report:
 - Any health care professional (Doctors including Dentists, Nurses and Pharmacists)
- Where to report:
 - Please return the completed form to the **Adverse Drug Reaction Monitoring Centre**
Department of Pharmacology
AIIMS, Bhopal.
Ph: 0755 – 2902620
Email: adr@aiimsbhopal.edu.in

Name of receiver:

Suspected Adverse Drug Reaction Reporting Form

For VOLUNTARY reporting of suspected adverse drug reactions by health care professionals



**National Coordinating Centre
Pharmacovigilance Programme of India
India Pharmacopoeia Commission**
Ministry of Health & Family Welfare
Government of India
Sector-23, Raj Nagar, Ghaziabad-201002
Tel.:0120-2783400, 2783401, 2783392,
FAX: 0120-2783311
www.ipc.nic.in

**Pharmacovigilance
Programme
of
India
for
Assuring Drug
Safety**

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. **Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.**